Published in:
Open Access
01-12-2014 | Research
CNS-targeted glucocorticoid reduces pathology in mouse model of amyotrophic lateral sclerosis
Authors:
Matthew C Evans, Pieter J Gaillard, Marco de Boer, Chantal Appeldoorn, Rick Dorland, Nicola R Sibson, Martin R Turner, Daniel C Anthony, Helen B Stolp
Published in:
Acta Neuropathologica Communications
|
Issue 1/2014
Login to get access
Abstract
Background
Hallmarks of CNS inflammation, including microglial and astrocyte activation, are prominent features in post-mortem tissue from amyotrophic lateral sclerosis (ALS) patients and in mice overexpressing mutant superoxide dismutase-1 (SOD1
G93A
). Administration of non-targeted glucocorticoids does not significantly alter disease progression, but this may reflect poor CNS delivery. Here, we sought to discover whether CNS-targeted, liposomal encapsulated glucocorticoid would inhibit the CNS inflammatory response and reduce motor neuron loss. SOD1
G93A
mice were treated with saline, free methylprednisolone (MP, 10 mg/kg/week) or glutathione PEGylated liposomal MP (2B3-201, 10 mg/kg/week) and compared to saline treated wild-type animals. Animals were treated weekly with intravenous injections for 9 weeks from 60 days of age. Weights and motor performance were monitored during this period. At the end of the experimental period (116 days) mice were imaged using T
2-weighted MRI for brainstem pathology; brain and spinal cord tissue were then collected for histological analysis.
Results
All SOD1
G93A
groups showed a significant decrease in motor performance, compared to baseline, from ~100 days. SOD1
G93A
animals showed a significant increase in signal intensity on T
2 weighted MR images, which may reflect the combination of neuronal vacuolation and glial activation in these motor nuclei. Treatment with 2B3-201, but not free MP, significantly reduced T
2 hyperintensity observed in SOD1
G93A
mice. Compared to saline-treated and free-MP-treated SOD1
G93A
mice, those animals given 2B3-201 displayed significantly improved histopathological outcomes in brainstem motor nuclei, which included reduced gliosis and neuronal loss.
Conclusions
In contrast to previous reports that employed free steroid preparations, CNS-targeted anti-inflammatory agent 2B3-201 (liposomal methylprednisolone) has therapeutic potential, reducing brainstem pathology in the SOD1
G93A
mouse model of ALS. 2B3-201 reduced neuronal loss and vacuolation in brainstem nuclei, and reduced activation preferentially in astrocytes compared with microglia. These data also suggest that other previously ineffective therapies could be of therapeutic value if delivered specifically to the CNS.